This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chute, J. P. Articles by Johnson, B. E. Search for Related Content PubMed PubMed Citation Articles by Chute, J. P. Articles by Johnson, B. E. Social Bookmarking                            What's this?

Twenty Years of Phase III Trials for Patients With Extensive-Stage Small-Cell Lung Cancer: Perceptible Progress

From the Naval Medical Research Institute and Division of Hematology/Oncology, National Naval Medical Center; and the Biometric Research Branch, Clinical Investigations Branch, and Medicine Branch, National Cancer Institute, Bethesda, MD.

Address reprint requests to Bruce E. Johnson, MD, Lung Cancer Biology Section, Medicine Branch, National Cancer Institute, Building 8, Room 5101, National Naval Medical Center, Bethesda, MD 20889-5105; email bejohnson{at}partners.org

PURPOSE: All cooperative group studies performed in North America for patients with extensive-stage small-cell lung cancer (SCLC) were evaluated to determine the pattern of the clinical trials and the outcome of patients over the past 20 years.

PATIENTS AND METHODS: Phase III trials for patients with extensive-stage SCLC were identified through a search of the National Cancer Institute Cancer Therapy Evaluation Program database from 1972 to 1993. Patients with extensive-stage SCLC treated during a similar time interval listed in the Surveillance, Epidemiology, and End Results (SEER) database were also examined. Trends were tested in the number of trials over time, the number and sex of patients entered onto the trials, and the survival time of patients treated over time.

RESULTS: Twenty-one phase III trials for patients with extensive-stage SCLC were initiated between 1972 and1990. The median of the median survival times of patients treated on the control arms of the phase III trials initiated between 1972 and 1981 was 7.0 months; for those patients enrolled onto control arms between 1982 and 1990, the median survival time was 8.9 months (P = .001). Analysis of the SEER database of patients with extensive-stage SCLC over the same time period shows a similar 2-month prolongation in median survival time.

CONCLUSION: Analysis of 21 phase III trials initiated in North America and the SEER database from 1972 to 1994 demonstrates that there has been a modest improvement in the survival time of patients with extensive-stage SCLC.

The views and opinions expressed herein are those of the authors and are not to be construed as the official opinion of the United States Navy or the Department of Defense.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				K. Hotta, K. Kiura, Y. Fujiwara, N. Takigawa, I. Oze, N. Ochi, M. Tabata, and M. Tanimoto Association between incremental gains in the objective response rate and survival improvement in phase III trials of first-line chemotherapy for extensive disease small-cell lung cancer Ann. Onc., May 1, 2009; 20(5): 829 - 834. [Abstract] [Full Text] [PDF]

				R. Ferraldeschi and P. Lorigan Extensive-stage small-cell lung cancer--moving beyond response rate? Ann. Onc., May 1, 2009; 20(5): 801 - 802. [Full Text] [PDF]

				G. Chen, M. Huynh, L. Fehrenbacher, H. West, P. N. Lara Jr, L. L. Yavorkovsky, M. Russin, D. Goldstein, D. Gandara, and D. Lau Phase II Trial of Irinotecan and Carboplatin for Extensive or Relapsed Small-Cell Lung Cancer J. Clin. Oncol., March 20, 2009; 27(9): 1401 - 1404. [Abstract] [Full Text] [PDF]

				S M Lee, L E James, W Qian, S Spiro, T Eisen, N H Gower, D R Ferry, D Gilligan, P G Harper, J Prendiville, et al. Comparison of gemcitabine and carboplatin versus cisplatin and etoposide for patients with poor-prognosis small cell lung cancer Thorax, January 1, 2009; 64(1): 75 - 80. [Abstract] [Full Text] [PDF]

				C. L. Hann, V. C. Daniel, E. A. Sugar, I. Dobromilskaya, S. C. Murphy, L. Cope, X. Lin, J. S. Hierman, D. L. Wilburn, D. N. Watkins, et al. Therapeutic Efficacy of ABT-737, a Selective Inhibitor of BCL-2, in Small Cell Lung Cancer Cancer Res., April 1, 2008; 68(7): 2321 - 2328. [Abstract] [Full Text] [PDF]

				T. Sher, G. K. Dy, and A. A. Adjei Small Cell Lung Cancer Mayo Clin. Proc., March 1, 2008; 83(3): 355 - 367. [Abstract] [Full Text] [PDF]

				D. H. Lee, S.-W. Kim, C. Suh, J.-S. Lee, J. H. Lee, S.-J. Lee, B. Y. Ryoo, K. Park, J. S. Kim, D. S. Heo, et al. Belotecan, new camptothecin analogue, is active in patients with small-cell lung cancer: results of a multicenter early phase II study Ann. Onc., January 1, 2008; 19(1): 123 - 127. [Abstract] [Full Text] [PDF]

				B. E. Johnson, C. M. Rudin, and R. Salgia Novel and Targeted Agents for Small Cell Lung Cancer ASCO Educational Book, January 1, 2008; 2008(1): 363 - 367. [Abstract] [Full Text] [PDF]

				M. Taniwaki, A. Takano, N. Ishikawa, W. Yasui, K. Inai, H. Nishimura, E. Tsuchiya, N. Kohno, Y. Nakamura, and Y. Daigo Activation of KIF4A as a Prognostic Biomarker and Therapeutic Target for Lung Cancer Clin. Cancer Res., November 15, 2007; 13(22): 6624 - 6631. [Abstract] [Full Text] [PDF]

				D. H. Lee, S.-W. Kim, K.-S. Bae, J.-S. Hong, C. Suh, Y.-K. Kang, and J.-S. Lee A Phase I and Pharmacologic Study of Belotecan in Combination with Cisplatin in Patients with Previously Untreated Extensive-Stage Disease Small Cell Lung Cancer Clin. Cancer Res., October 15, 2007; 13(20): 6182 - 6186. [Abstract] [Full Text] [PDF]

				G. R. Simon and A. Turrisi Management of Small Cell Lung Cancer: ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition) Chest, September 1, 2007; 132(3_suppl): 324S - 339S. [Abstract] [Full Text] [PDF]

				B. Slotman, C. Faivre-Finn, G. Kramer, E. Rankin, M. Snee, M. Hatton, P. Postmus, L. Collette, E. Musat, S. Senan, et al. Prophylactic Cranial Irradiation in Extensive Small-Cell Lung Cancer N. Engl. J. Med., August 16, 2007; 357(7): 664 - 672. [Abstract] [Full Text] [PDF]

				R. Jagadeeswaran, S. Jagadeeswaran, V. P. Bindokas, and R. Salgia Activation of HGF/c-Met pathway contributes to the reactive oxygen species generation and motility of small cell lung cancer cells Am J Physiol Lung Cell Mol Physiol, June 1, 2007; 292(6): L1488 - L1494. [Abstract] [Full Text] [PDF]

				A. W. Blackstock, J. E. Herndon II, E. D. Paskett, A. A. Miller, C. Lathan, H. B. Niell, M. A. Socinski, E. E. Vokes, and M. R. Green Similar Outcomes Between African American and Non-African American Patients With Extensive-Stage Small-Cell Lung Carcinoma: Report From the Cancer and Leukemia Group B J. Clin. Oncol., January 20, 2006; 24(3): 407 - 412. [Abstract] [Full Text] [PDF]

				N. Thatcher, W. Qian, P. I. Clark, P. Hopwood, R. J. Sambrook, R. Owens, R. J. Stephens, and D. J. Girling Ifosfamide, Carboplatin, and Etoposide With Midcycle Vincristine Versus Standard Chemotherapy in Patients With Small-Cell Lung Cancer and Good Performance Status: Clinical and Quality-of-Life Results of the British Medical Research Council Multicenter Randomized LU21 Trial J. Clin. Oncol., November 20, 2005; 23(33): 8371 - 8379. [Abstract] [Full Text] [PDF]

				M. I. Zia, L. L. Siu, G. R. Pond, and E. X. Chen Comparison of Outcomes of Phase II Studies and Subsequent Randomized Control Studies Using Identical Chemotherapeutic Regimens J. Clin. Oncol., October 1, 2005; 23(28): 6982 - 6991. [Abstract] [Full Text] [PDF]

				H. B. Niell, J. E. Herndon II, A. A. Miller, D. M. Watson, A. B. Sandler, K. Kelly, R. S. Marks, M. C. Perry, R. H. Ansari, G. Otterson, et al. Randomized Phase III Intergroup Trial of Etoposide and Cisplatin With or Without Paclitaxel and Granulocyte Colony-Stimulating Factor in Patients With Extensive-Stage Small-Cell Lung Cancer: Cancer and Leukemia Group B Trial 9732 J. Clin. Oncol., June 1, 2005; 23(16): 3752 - 3759. [Abstract] [Full Text] [PDF]

				P. Lorigan, P. J. Woll, M. E. R. O'Brien, L. F. Ashcroft, M. R. Sampson, and N. Thatcher Randomized Phase III Trial of Dose-Dense Chemotherapy Supported by Whole-Blood Hematopoietic Progenitors in Better-Prognosis Small-Cell Lung Cancer J Natl Cancer Inst, May 4, 2005; 97(9): 666 - 674. [Abstract] [Full Text] [PDF]

				G. S. Warshamana-Greene, J. Litz, E. Buchdunger, C. Garcia-Echeverria, F. Hofmann, and G. W. Krystal The Insulin-Like Growth Factor-I Receptor Kinase Inhibitor, NVP-ADW742, Sensitizes Small Cell Lung Cancer Cell Lines to the Effects of Chemotherapy Clin. Cancer Res., February 15, 2005; 11(4): 1563 - 1571. [Abstract] [Full Text] [PDF]

				H. Rostad, A. Naalsund, R. Jacobsen, T. E. Strand, H. Scott, E. H. Strom, and J. Norstein Small cell lung cancer in Norway. Should more patients have been offered surgical therapy? Eur. J. Cardiothorac. Surg., October 1, 2004; 26(4): 782 - 786. [Abstract] [Full Text] [PDF]

				J. V. Heymach, D. H. Johnson, F. R. Khuri, H. Safran, L. L. Schlabach, F. Yunus, R. F. DeVore III, P. M. De Porre, H. M. Richards, X. Jia, et al. Phase II study of the farnesyl transferase inhibitor R115777 in patients with sensitive relapse small-cell lung cancer Ann. Onc., August 1, 2004; 15(8): 1187 - 1193. [Abstract] [Full Text] [PDF]

				B. E. Johnson Imatinib for Small Cell Lung Cancer, Aiming for a Target in Vivo Clin. Cancer Res., May 15, 2004; 10(10): 3235 - 3236. [Full Text] [PDF]

				N. C. Wolff, D. E. Randle, M. J. Egorin, J. D. Minna, and R. L. Ilaria Jr. Imatinib Mesylate Efficiently Achieves Therapeutic Intratumor Concentrations in Vivo but Has Limited Activity in a Xenograft Model of Small Cell Lung Cancer Clin. Cancer Res., May 15, 2004; 10(10): 3528 - 3534. [Abstract] [Full Text] [PDF]

				C. M. Rudin, M. Kozloff, P. C. Hoffman, M. J. Edelman, R. Karnauskas, R. Tomek, L. Szeto, and E. E. Vokes Phase I Study of G3139, a bcl-2 Antisense Oligonucleotide, Combined With Carboplatin and Etoposide in Patients With Small-Cell Lung Cancer J. Clin. Oncol., March 15, 2004; 22(6): 1110 - 1117. [Abstract] [Full Text] [PDF]

				B. E. Johnson, T. Fischer, B. Fischer, D. Dunlop, D. Rischin, S. Silberman, M. O. Kowalski, D. Sayles, S. Dimitrijevic, C. Fletcher, et al. Phase II Study of Imatinib in Patients with Small Cell Lung Cancer Clin. Cancer Res., December 1, 2003; 9(16): 5880 - 5887. [Abstract] [Full Text] [PDF]

				P. C. Ma, T. Kijima, G. Maulik, E. A. Fox, M. Sattler, J. D. Griffin, B. E. Johnson, and R. Salgia c-MET Mutational Analysis in Small Cell Lung Cancer: Novel Juxtamembrane Domain Mutations Regulating Cytoskeletal Functions Cancer Res., October 1, 2003; 63(19): 6272 - 6281. [Abstract] [Full Text] [PDF]

				J. Laskin, A. Sandler, and D. H. Johnson An Advance in Small-Cell Lung Cancer Treatment--More or Less J Natl Cancer Inst, August 6, 2003; 95(15): 1099 - 1101. [Full Text] [PDF]

				A. Potti, N. Moazzam, K. Ramar, D. S. Hanekom, S. Kargas, and M. Koch CD117 (c-KIT) overexpression in patients with extensive-stage small-cell lung carcinoma Ann. Onc., June 1, 2003; 14(6): 894 - 897. [Abstract] [Full Text] [PDF]

				B. Freidlin, O. S. Breathnach, and B. E. Johnson A Model to Select Regimens for Phase III Trials for Patients with Advanced-Stage Non-Small Cell Lung Cancer Clin. Cancer Res., March 1, 2003; 9(3): 917 - 922. [Abstract] [Full Text] [PDF]

				P. Micke, M. Basrai, A. Faldum, F. Bittinger, L. Ronnstrand, A. Blaukat, K. M. Beeh, F. Oesch, B. Fischer, R. Buhl, et al. Characterization of c-kit Expression in Small Cell Lung Cancer: Prognostic and Therapeutic Implications Clin. Cancer Res., January 1, 2003; 9(1): 188 - 194. [Abstract] [Full Text] [PDF]

				G. R. Simon and H. Wagner Small Cell Lung Cancer Chest, January 1, 2003; 123 (2009): 259S - 271S. [Abstract] [Full Text] [PDF]

				D. H. Johnson "The Guard Dies, It Does Not Surrender!" Progress in the Management of Small-Cell Lung Cancer? J. Clin. Oncol., December 15, 2002; 20(24): 4618 - 4620. [Full Text] [PDF]

				J L Mulshine and R A Smith Lung cancer * 2: Screening and early diagnosis of lung cancer Thorax, December 1, 2002; 57(12): 1071 - 1078. [Abstract] [Full Text] [PDF]

				S. G. Spiro and J. C. Porter Lung Cancer--Where Are We Today?: Current Advances in Staging and Nonsurgical Treatment Am. J. Respir. Crit. Care Med., November 1, 2002; 166(9): 1166 - 1196. [Abstract] [Full Text] [PDF]

				V. C. G. Tjan-Heijnen, D. J. T. Wagener, and P. E. Postmus An analysis of chemotherapy dose and dose-intensity in small-cell lung cancer: lessons to be drawn Ann. Onc., October 1, 2002; 13(10): 1519 - 1530. [Abstract] [Full Text] [PDF]

				C. N. Papandreou, D. D. Daliani, P. F. Thall, S.-M. Tu, X. Wang, A. Reyes, P. Troncoso, and C. J. Logothetis Results of a Phase II Study With Doxorubicin, Etoposide, and Cisplatin in Patients With Fully Characterized Small-Cell Carcinoma of the Prostate J. Clin. Oncol., July 15, 2002; 20(14): 3072 - 3080. [Abstract] [Full Text] [PDF]

				G. Maulik, T. Kijima, P. C. Ma, S. K. Ghosh, J. Lin, G. I. Shapiro, E. Schaefer, E. Tibaldi, B. E. Johnson, and R. Salgia Modulation of the c-Met/Hepatocyte Growth Factor Pathway in Small Cell Lung Cancer Clin. Cancer Res., February 1, 2002; 8(2): 620 - 627. [Abstract] [Full Text] [PDF]

				D. N. Carney Lung Cancer -- Time to Move on from Chemotherapy N. Engl. J. Med., January 10, 2002; 346(2): 126 - 128. [Full Text] [PDF]

				K. Osterlind Chemotherapy in small cell lung cancer Eur. Respir. J., December 1, 2001; 18(6): 1026 - 1043. [Abstract] [Full Text] [PDF]

				K. Kelly, L. Lovato, P. A. Bunn Jr., R. B. Livingston, J. Zangmeister, S. A. Taylor, D. Roychowdhury, J. J. Crowley, and D. R. Gandara Cisplatin, Etoposide, and Paclitaxel with Granulocyte Colony-Stimulating Factor in Untreated Patients with Extensive-Stage Small Cell Lung Cancer: A Phase II Trial of the Southwest Oncology Group Clin. Cancer Res., August 1, 2001; 7(8): 2325 - 2329. [Abstract] [Full Text] [PDF]

				O. S. Breathnach, B. Freidlin, B. Conley, M. R. Green, D. H. Johnson, D. R. Gandara, M. O'Connell, F. A. Shepherd, and B. E. Johnson Twenty-Two Years of Phase III Trials for Patients With Advanced Non-Small-Cell Lung Cancer: Sobering Results J. Clin. Oncol., March 15, 2001; 19(6): 1734 - 1742. [Abstract] [Full Text] [PDF]

				T. T. Chen, J. P. Chute, E. Feigal, B. E. Johnson, and R. Simon RESPONSE: Re: A Model to Select Chemotherapy Regimens for Phase III Trials for Extensive-Stage Small-Cell Lung Cancer J Natl Cancer Inst, March 7, 2001; 93(5): 400 - 401. [Full Text] [PDF]

				B. E. Johnson Is More Better? Chemotherapy for Patients With Extensive-Stage Small-Cell Lung Cancer J Natl Cancer Inst, February 21, 2001; 93(4): 254 - 255. [Full Text] [PDF]

				J.-L. Pujol, J.-P. Daures, A. Riviere, E. Quoix, V. Westeel, X. Quantin, J.-L. Breton, E. Lemarie, M. Poudenx, B. Milleron, et al. Etoposide Plus Cisplatin With or Without the Combination of 4'-Epidoxorubicin Plus Cyclophosphamide in Treatment of Extensive Small-Cell Lung Cancer: a French Federation of Cancer Institutes Multicenter Phase III Randomized Study J Natl Cancer Inst, February 21, 2001; 93(4): 300 - 308. [Abstract] [Full Text] [PDF]

				C. Kosmas, N. B. Tsavaris, N. A. Malamos, M. Vadiaka, and C. Koufos Phase II Study of Paclitaxel, Ifosfamide, and Cisplatin as Second-Line Treatment in Relapsed Small-Cell Lung Cancer J. Clin. Oncol., January 1, 2001; 19(1): 119 - 126. [Abstract] [Full Text] [PDF]

				T. T. Chen, J. P. Chute, E. Feigal, B. E. Johnson, and R. Simon A Model to Select Chemotherapy Regimens for Phase III Trials for Extensive-Stage Small-Cell Lung Cancer J Natl Cancer Inst, October 4, 2000; 92(19): 1601 - 1607. [Abstract] [Full Text] [PDF]